Delays in starting radiotherapy can increase risk of cancer recurrence
In both breast and head and neck cancers the risk of local recurrence increases with longer radiotherapy waiting times, a Canadian meta-analysis has found. The study, published in Radiotherapy and Oncology, concludes that delays in radiotherapy treatment should be kept to the minimum possible.
Waiting times for radiotherapy were first identified as cause for concern around 20 years ago. Treatment delays can be attributed to increasing demands for radiotherapy caused by the growing incidence of cancer due to an ageing population and the discovery and adoption of new indications for radiotherapy. “When the increasing demand is not matched by a commensurate increase in treatment capacity, waiting lists for RT become inevitable,” write the authors Zheng Chen and colleagues, from Queen’s Cancer Research Institute (Kingston, Ontario, Canada) and Cross Cancer Institute (Edmonton, Alta, Canada).
Experimental evidence has suggested that the probability of eradicating a tumour by radiotherapy can be inversely related to the number of clonogenic cells it contains, and there is also clinical evidence that the probability of local control in many different types of human cancer can be inversely related to the volume of the cancer. Two recent studies have demonstrated clear evidence of tumour progression in a high proportion of patients waiting to start radiotherapy for head and neck cancer.
In the current study, Chen and colleagues set about trying to provide direct evidence that waiting times for radiotherapy influence patient’s clinical outcomes. The study was initiated in response to a request from the Canadian government for assistance to provide “evidence-based benchmarks” for waiting times for selected procedures, including cancer treatment, cardiac surgery, joint replacements, cataract surgery and diagnostic imaging. Since it would be clearly unethical to perform a randomised trial exploring treatment delays, the investigators undertook a systematic literature to identify clinical studies published between 1975 and 2005 describing a relationship between waiting times and outcomes of radiotherapy. Altogether they identified 44 retrospective observational cohort studies, of which 20 met the high quality criteria for inclusion in the meta-analysis. High quality criteria included comparative groups being balanced with respect to relevant prognostic factors, and reported results being appropriately adjusted for differences in relevant prognostic factors.
For each cancer considered by the meta-analysis, the mean of the local recurrence rates reported in the groups with the shortest waiting time was used to estimate a baseline for local recurrence. For breast cancer the mean baseline rate of local recurrence following post-operative radiotherapy was 8.5 % (with a range of 2.0 to 13 %), with each month of delay in starting radiotherapy found to produce an absolute increase in the risk of recurrence of 1.0 %. For head and neck cancer, the mean baseline rate of local recurrence following post operative radiotherapy was 22.7 % (range 9.9 to 25.5%), with each month of delay found to produce an absolute increase in the risk of recurrence of 6.3 %. For head and neck cancer radiotherapy, taking place without an operation, the mean baseline rate of local recurrence was 24.7 % (range (9.0-27 %), with each month of delay found to translate into an absolute increase in the risk of recurrence of 3.7 % per month of delay.
In contrast, the study found little evidence of an association between delays in radiotherapy and the risk of distant metastasis. There is no evidence to suggest that the relationship between delay in radiotherapy and local recurrence is unique to these two cancer sites, write the authors. However, to date there hav
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.